These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 31314757)

  • 1. Onchocerciasis-associated epilepsy in the Democratic Republic of Congo: Clinical description and relationship with microfilarial density.
    Siewe Fodjo JN; Mandro M; Mukendi D; Tepage F; Menon S; Nakato S; Nyisi F; Abhafule G; Wonya'rossi D; Anyolito A; Lokonda R; Hotterbeekx A; Colebunders R
    PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007300. PubMed ID: 31314757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High prevalence of epilepsy in an onchocerciasis endemic health zone in the Democratic Republic of the Congo, despite 14 years of community-directed treatment with ivermectin: A mixed-method assessment.
    Mukendi D; Tepage F; Akonda I; Siewe JNF; Rotsaert A; Ndibmun CN; Laudisoit A; Couvreur S; Kabutako B; Menon S; Hotterbeekx A; Colebunders R
    Int J Infect Dis; 2019 Feb; 79():187-194. PubMed ID: 30711145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persons with onchocerciasis-associated epilepsy and nodding seizures have a more severe form of epilepsy with more cognitive impairment and higher levels of Onchocerca volvulus infection.
    Abd-Elfarag G; Carter JY; Raimon S; Sebit W; Suliman A; Fodjo JNS; Olore PC; Biel KP; Ojok M; Logora MY; Colebunders R
    Epileptic Disord; 2020 Jun; 22(3):301-308. PubMed ID: 32540799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ivermectin as an adjuvant to anti-epileptic treatment in persons with onchocerciasis-associated epilepsy: A randomized proof-of-concept clinical trial.
    Mandro M; Siewe Fodjo JN; Mukendi D; Dusabimana A; Menon S; Haesendonckx S; Lokonda R; Nakato S; Nyisi F; Abhafule G; Wonya'Rossi D; Jakwong JM; Suykerbuyk P; Meganck J; Hotterbeekx A; Colebunders R
    PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007966. PubMed ID: 31923177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Onchocerca volvulus as a risk factor for developing epilepsy in onchocerciasis endemic regions in the Democratic Republic of Congo: a case control study.
    Mandro M; Suykerbuyk P; Tepage F; Rossy D; Ngave F; Hasan MN; Hotterbeekx A; Mambandu G; Kashama JM; Laudisoit A; Colebunders R
    Infect Dis Poverty; 2018 Oct; 7(1):79. PubMed ID: 30293530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical presentations of onchocerciasis-associated epilepsy (OAE) in Cameroon.
    Siewe JFN; Ngarka L; Tatah G; Mengnjo MK; Nfor LN; Chokote ES; Boullé C; Nkouonlack C; Dema F; Nkoro GA; Njamnshi WY; Tabah EN; Zoung-Kanyi Bissek AC; Colebunders R; Njamnshi AK
    Epilepsy Behav; 2019 Jan; 90():70-78. PubMed ID: 30513438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics of onchocerciasis-associated epilepsy in villages in Maridi County, Republic of South Sudan.
    Colebunders R; Abd-Elfarag G; Carter JY; Olore PC; Puok K; Menon S; Fodjo Siewe JN; Bhattacharyya S; Ojok M; Lako R; Logora MY
    Seizure; 2018 Nov; 62():108-115. PubMed ID: 30340162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High prevalence of epilepsy in onchocerciasis endemic health areas in Democratic Republic of the Congo.
    Lenaerts E; Mandro M; Mukendi D; Suykerbuyk P; Dolo H; Wonya'Rossi D; Ngave F; Ensoy-Musoro C; Laudisoit A; Hotterbeekx A; Colebunders R
    Infect Dis Poverty; 2018 Aug; 7(1):68. PubMed ID: 30064504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for epilepsy in Bas-Uélé Province, Democratic Republic of the Congo: a case-control study.
    Colebunders R; Mandro M; Mokili JL; Mucinya G; Mambandu G; Pfarr K; Reiter-Owona I; Hoerauf A; Tepage F; Levick B; Begon M; Laudisoit A
    Int J Infect Dis; 2016 Aug; 49():1-8. PubMed ID: 27210267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High prevalence of epilepsy in onchocerciasis endemic regions in the Democratic Republic of the Congo.
    Levick B; Laudisoit A; Tepage F; Ensoy-Musoro C; Mandro M; Bonareri Osoro C; Suykerbuyk P; Kashama JM; Komba M; Tagoto A; Falay D; Begon M; Colebunders R
    PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005732. PubMed ID: 28708828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical presentation of epilepsy in six villages in an onchocerciasis endemic area in Mahenge, Tanzania.
    Bhwana D; Mmbando BP; Dekker MC; Mnacho M; Kakorozya A; Matuja W; Makunde WH; Weckhuysen S; Colebunders R
    Epileptic Disord; 2019 Oct; 21(5):425-435. PubMed ID: 31649005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Ivermectin Treatment on the Frequency of Seizures in Persons with Epilepsy Infected with
    Dusabimana A; Tsebeni Wafula S; Raimon SJ; Fodjo JNS; Bhwana D; Tepage F; Abd-Elfarag G; Hotterbeekx A; Abrams S; Colebunders R
    Pathogens; 2020 Dec; 10(1):. PubMed ID: 33396221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ivermectin treatment response in two rural villages with a high prevalence of onchocerciasis and epilepsy, Mahenge Tanzania.
    Bhwana D; Mmbando BP; Dusabimana A; Mhina A; Challe DP; Fodjo JNS; Makunde WH; Colebunders R
    Afr Health Sci; 2022 Sep; 22(3):607-616. PubMed ID: 36910370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of ivermectin on onchocerciasis in villages co-endemic for lymphatic filariasis in an area of onchocerciasis recrudescence in Burkina Faso.
    Nikièma AS; Koala L; Sondo AK; Post RJ; Paré AB; Kafando CM; Kambiré RS; Sow B; Bougouma C; Dabiré RK; Traoré S
    PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009117. PubMed ID: 33647010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology of onchocerciasis-associated epilepsy in the Mbam and Sanaga river valleys of Cameroon: impact of more than 13 years of ivermectin.
    Siewe Fodjo JN; Tatah G; Tabah EN; Ngarka L; Nfor LN; Chokote SE; Mengnjo MK; Dema F; Sitouok AT; Nkoro G; Ntone FE; Bissek AZ; Chesnais CB; Boussinesq M; Colebunders R; Njamnshi AK
    Infect Dis Poverty; 2018 Dec; 7(1):114. PubMed ID: 30501640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population dynamics of onchocerca volvulus microfilariae in human host after six years of drug control.
    Opara KN; Fagbemi BO
    J Vector Borne Dis; 2008 Mar; 45(1):29-37. PubMed ID: 18399314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onchocerciasis-associated epilepsy: an update and future perspectives.
    Hadermann A; Amaral LJ; Van Cutsem G; Siewe Fodjo JN; Colebunders R
    Trends Parasitol; 2023 Feb; 39(2):126-138. PubMed ID: 36528471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial.
    Opoku NO; Bakajika DK; Kanza EM; Howard H; Mambandu GL; Nyathirombo A; Nigo MM; Kasonia K; Masembe SL; Mumbere M; Kataliko K; Larbelee JP; Kpawor M; Bolay KM; Bolay F; Asare S; Attah SK; Olipoh G; Vaillant M; Halleux CM; Kuesel AC
    Lancet; 2018 Oct; 392(10154):1207-1216. PubMed ID: 29361335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of Onchocerca volvulus in the development of epilepsy in a rural area of Tanzania.
    König R; Nassri A; Meindl M; Matuja W; Kidunda AR; Siegmund V; Bretzel G; Löscher T; Jilek-Aall L; Schmutzhard E; Winkler AS
    Parasitology; 2010 Sep; 137(10):1559-68. PubMed ID: 20388236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low prevalence of epilepsy and onchocerciasis after more than 20 years of ivermectin treatment in the Imo River Basin in Nigeria.
    Siewe JNF; Ukaga CN; Nwazor EO; Nwoke MO; Nwokeji MC; Onuoha BC; Nwanjor SO; Okeke J; Osahor K; Chimechefulam L; Ogomaka AI; Amaechi AA; Ezenwa CI; Ezike MN; Ikpeama C; Nwachukwu O; Eriama-Joseph AI; Nwoke BEB; Colebunders R
    Infect Dis Poverty; 2019 Jan; 8(1):8. PubMed ID: 30670093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.